Join
Live feed
·
PRReleasevia Quantisnow
Soligenix Inc. logo

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
SNGX· Soligenix Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNGX (Soligenix Inc.) and more on Quantisnow.